Table 2.
Demographic data and analysis results for study population.
| Parameter | All | Training and Internal Validation Sets (n = 149) |
External Validation Set (n = 22) |
p Value |
|---|---|---|---|---|
| Mean Age, years [range] | 69.2982 [47–84] | 69.2483 [47–84] | 69.6364 [56–80] | 0.8049 |
| Mean PSA, ng/mL [range] | 14.6315 [0.85–149] | 14.4478 [0.85–149] | 21.1709 [3.0–131] | 0.3597 |
| GS, n (%) | ||||
| 6 | 46 (27) | 40 (27) | 6 (27) | 0.9307 |
| 7 | 125 (73) | 109 (73) | 16 (73) | 0.9912 |
| 3 + 4 | 89 | 76 | 13 | |
| 4 + 3 | 36 | 33 | 3 | |
| PIRADS v2.1, n (%) | ||||
| 3 | 17 (10) | 17 (11) | 0 (0) | 0.1131 |
| 4 | 55 (32) | 49 (33) | 6 (27) | 0.7006 |
| 5 | 99 (58) | 83 (56) | 16 (73) | 0.3307 |
| Tumor location, n (%) | ||||
| Peripheral zone | 92 (54) | 81 (54) | 11 (50) | 0.8245 |
| Transitional zone | 48 (28) | 38 (26) | 10 (45) | 0.1204 |
| Fibromuscular zone | 4 (2) | 4 (3) | 0 (0) | 0.4422 |
| Diffuse | 27 (16) | 26 (17) | 1 (5) | 0.1453 |
GS, Gleason score; PSA, prostate-specific antigen.